To determine if expression of the v-myc oncogene had any effect during ontogeny, we i wected avian myelocytomatosis virus strain MC29 into avian embryos at various stages of development. The injection of MC29 at embryonic day 2 (E2) or 3 (E3) caused, about 10 days later, rhabdomyosarcomas of the heart and, in some cases, skin muscle hypertrophy. When the injection was performed at E4 or E5, the number of heart tumors declined, whereas the number of skin muscle tumors increased significantly. The pll1gagmYc protein was found in all tumors analyzed. When the virus was injected intravenously into E10 embryos, no tumors appeared during embryonic life, in striking contrast to the results obtained from injections at earlier stages. The monoclonal antibody 13F4, which is specific for the myogenic lineage, bound strongly to tumoral heart tissue, whereas it bound weakly to normal cardiac cells. Comparison of the peaks of tumor incidence in relationship to the timing of injection suggests that the v-myc product could interfere in vivo with an early step of the muscle lineage differentiation program. In addition, we show that the p58c-mYc protein, which is supposed to play an important role in the control of cell proliferation, is only faintly detected in the heart of normal E3 embryos, in contrast to limb and tail buds, which readily express detectable levels of p58c.myc.
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The avian myelocytomatosis virus strain MC29 (a replication-defective acute leukemia virus) containing the v-myc oncogene induces neoplastic diseases in chicken, including myelocytomatosis, lymphomas, and also kidney and liver tumors (1) (2) (3) . The c-myc and v-myc gene products are known to play an important role in the control of cell proliferation (4) (5) (6) , and during terminal differentiation of a variety of cells, the level of c-myc mRNA decreases markedly (7) (8) (9) . In vitro, MC29-induced transformation is often accompanied by disorganization in the expression of cell-specific differentiated functions (2, 10) . Constitutive c-myc gene expression has been shown to block dimethyl sulfoxide-induced differentiation into mouse erythroleukemia cells (11) . Therefore, the myc oncogene product may induce transformation by blocking differentiation in appropriate cells. However, the participation of oncogenes in the differentiation of a pluripotent stem cell to a terminal differentiated cell remains largely obscure, and some aspects cannot be satisfactorily studied in vitro. To overcome this limitation, we used an in vivo experimental approach; we injected MC29 virus into avian embryos at various stages of development. This approach has uncovered a striking effect of the v-myc oncogene during development of the avian embryo.
The injection of MC29 at embryonic day 2 (E2) or 3 (E3) of incubation caused rhabdomyosarcomas of the heart and, less frequently, skin muscle tumors. When the injection was performed at E4 or E5, we found primarily skin muscle tumors. These results suggest that the v-myc product could interfere specifically with an early step of the muscle differentiation program since other embryonic tissues without detectable tumors became transformed after in vitro propagation.
MATERIALS AND METHODS
Cell Culture and Viruses. The supernatant used in injections was obtained from quail embryo cells transfected as previously described (12) with 30 (13) . MH2 was rescued from molecular clone pMH2Hd (16) . Avian erythroblastosis virus (AEV) and avian myelocytomatosis virus (AMV) were previously described (6) . Other tumors refer to skin muscle tumors with MC29 and to one liver tumor with MH2. Embryos were injected at E2-E3 and were recovered at E12-E18. (14) . Tumoral tissue (T) had a strong affinity for 13F4, while normal heart (H) at this stage (E19) has only a weak affinity. QH1, a nonrelevant antibody which is specific for the quail hemangioblastic lineage (17) Fig. la) . These tumors were located on the outside aspect of the ventricles. The size and number of tumors on each affected heart were variable. Upon macroscopic examination, the only other anomalies in these embryos were found on areas of the skin where the feathers appeared bell-shaped (Fig. 2a) . When these areas were processed for cytological examination, underlying striated skin muscle was overdeveloped, but it seemed to retain a normal organization (Fig. 2 b and c) . In four cases, embryos injected at E3 hatched; all of them carried multiple skin muscle tumors that clearly showed abnormal cells. Internal organs ofthe injected embryos never displayed visible tumors. The frequency of heart tumors declined sharply from 72% on injection at E3 to 2% on injection at E5, whereas bell-shaped feathers increased up to 71% (Fig. 3) . When the virus was injected intravenously at E10 (100-500 ffu), no cardiac tumors were detected. By contrast, tumors of hemopoietic cell origin were observed, which could be located on almost any organ (data not shown); these tumors were found only after hatching, from the 12th day onward. Heart tumors specifically appear to be caused by the v-myc-containing retroviruses MC29 and MH2. Avian erythroblastosis virus (containing v-erbA and v-erbB), avian myelocytomatosis (carrying the v-myb oncogene), or RAV-1 helper virus alone were unable to induce tumors in these embryos (Table 1) .
Heart tumors were not restricted to the White Leghorn chicken strain, since similar results were obtained in Golden Leghorn embryos. In' quail embryos injected -at E3, the incidence of heart tumors was 100% (Table 2 ). Furthermore, in quail, these tumors appeared within an extremely short time frame. At E9 multiple tumoral foci were found within the hearts, and at Eli most embryos were dead; all of them displayed macroscopic tumors.
Muscle Cells Were Transformed. Several arguments lead us to conclude that the transformed cells are myocytes. The tumors were in direct continuity with normal heart tissue ( Fig. lb) . They had a strong affinity for monoclonal antibody 13F4 (Fig. ic) , which is specific for the avian myogenic lineage (14) . Ultrastructural examination revealed that a few cells at the edge of the tumors displayed vestigial myofibrils, Z bands, and intercalated disks (Fig. ld) (Fig. 4, lanes 1 ) or anti-myc (12, 15) (Fig. 4, lanes 2 five quail embryos carrying heart tumors. These tissues were found free of detectable tumors; however, after 1 week ii culture, cells from most of them were found to be morpho logically transformed and contained the p1109lltYc proteil (data not shown). All livers gave rise to transformed cells.
p58c-Myc Protein in E3 Embryo Hearts. We next examine( if there is a correlation between c-myc expression in E1 embryos and "susceptibility" to v-myc oncogene-induce( heart tumors. Forty chicken embryo hearts were dissected and limb and tail buds were retrieved as a control. These were mechanically disrupted, and 3 x 106 cells were incubated foi 1 hr in DMEM at 370C with 0.5 mCi of [35S]cysteine. In ordei to obtain a standard of c-myc expression, 3 x 106 cells of the lymphoblastoid T-cell line MSBI were similarly labeled MSBI cells have been shown to contain 50 copies of c-myc RNA (6). Extracts of [35S]cysteine labeled cells were im munoprecipitated with a rabbit anti-myc serum. The endog enous chicken c-myc protein (18) was only faintly detected in the heart, whereas a similar high amount of p58c-myc was found in control tissues and MSBI cells (Fig. 5 ).
DISCUSSION
Our experiments have uncovered a striking and unexpected tumorigenic effect of the v-myc oncogene affecting muscle tissue in the developing avian embryo. This effect is unexpected because of its tissue specificity and time restriction. First, transformed cells were heart and skin myocytes, whereas myocytes have never been described as in vivo targets for this oncogene. Second, heart myocytes were transformed only if the virus was injected before E4, and skin myocytes were transformed if the virus was injected between E2 and E5 but not at E10 (for technical reasons no embryos differentiation occurred along the myogenic differentiation c pathway. Indeed, it has been shown previously that v-myc is able to inhibit the differentiation of quail myogenic cells in vitro (10) . Injections performed at E10 gave rise to completely different tumors, which were hemopoietic in origin and s developed only after hatching. These results contrast with former reports on tumorigenesis in embryos. The instance most relevant to our work has been described by Dolberg and Bissell (19) . These authors have injected Rous sarcoma virus (RSV) particles into the limb bud of E4 chicken embryos. No tumors ever developed, even though the virus became integrated in the host genome, multiplied, and expressed its specific kinase activity. By contrast, RSV injected into the wing web of newly hatched chickens induced palpable tumors within a week. Similarly in our hands, avian myelocytomatosis and erythroblastosis viruses were unable to induce tumors in the embryo. However, since the targets for these viruses are mainly hemopoietic cells and anomalies-in this lineage are difficult to appreciate in the embryo because of the changing blood cell makeup, a detailed analysis is necessary. Other cases have been reported where transformed cells were controlled by the embryonic microenvironment (20) (21) (22) (23) . In several transgenic mice families constructed with myc genes associated to various promoters, no tumors have been described during fetal development (24) (25) (26) . Recently, however, a line has been described in which the activated human c-Ha-ras oncogene is under control ofrat elastase I regulating elements (27) . In most transgenic mice bearing this gene construct, tumors of the exocrine pancreas developed as soon as exocrine cells began differentiating. In this work, a construct involving the c-myc gene and the same regulator elements produced no tumors (27) .
Why did MC29 induce only striated muscle tumors (heart and skin) in young embryos? Several cell types or organs from the young embryo have been efficiently transformed in vitro (e.g., fibroblasts, somites, and neural tube; S.S., unpublished data), but in vivo these cells were "resistant" to the v-myc oncogene. It seems unlikely that only heart cells have receptors for the virus during the early period of development and that these receptors disappear when myoblasts differentiate. Indeed, when several organs from the injected embryos were seeded in culture, morphological transformation be-came rapidly evident, suggesting that in ovo unknown factors must control the appearance of the transformed phenotype in most tissues. It is also possible that other factors whose expressions are time and tissue specific should interact with v-myc to facilitate cell transformation. Of interest in this respect is the observation of Massagud et al. (28) showing that type 8 transforming growth factor, a hormonally active polypeptide found in normal and transformed tissues, is an inhibitor of myogenic differentiation.
Among the nine embryos injected at E3 with MH2, one developed liver tumors in ovo. This result sugggests that myoblasts may be transformed by v-myc alone and that a second event (in this case, the v-mil product) is necessary to transform other tissues in the young embryo. Interestingly, among the four embryos injected with MC29 at E3 that hatched, one displayed multiple tumoral foci in the liver and an adrenal tumor, suggesting that these organs could be targets for v-myc later in their development. Comparison of the peaks of tumor incidence in relationship to the timing of injection suggests that the v-myc product could interfere with an early step of the muscle lineage differentiation program, since heart myoblasts begin to differentiate as early as the 8-somite stage (29) , whereas skeletal myoblast precursors first arrive in their differentiation site at the 26-somite stage (30, 31) . In any case, the transforming potential of MC29 is clearly different in vitro and in vivo and changes as development proceeds. In our experiments, it seems that constitutive myc gene expression above a certain threshold may promote cell division at the expense of differentiation. However, it is possible that one or several other developmentally related conditions must be met before the tumoral phenotype could be expressed in infected tissues.
